What is Paratek Pharmaceuticals Profitability Rank?
Paratek Pharmaceuticals has the Profitability Rank of 3. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Paratek Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2023 was -24.73%. As of today, Paratek Pharmaceuticals's Piotroski F-Score is 5.
Competitive Comparison of Paratek Pharmaceuticals's Profitability Rank
For the Biotechnology subindustry, Paratek Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paratek Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Paratek Pharmaceuticals's Profitability Rank falls into.
Paratek Pharmaceuticals Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Paratek Pharmaceuticals has the Profitability Rank of 3. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Paratek Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Paratek Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Paratek Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Executives
| Minnie Baylor-henry |
director |
C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
| Kristine Peterson |
director |
AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355 |
| Timothy R Franson |
director |
320 WAKARA WAY, SALT LAKE CITY UT 84108 |
| Jeffrey Stein |
director |
6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
| Thomas John Dietz |
director |
C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804 |
| Evan Loh |
director, officer: CEO |
75 KNEELAND STREET, BOSTON MA 02111 |
| William M. Haskel |
officer: CLO, General Counsel & Sec. |
ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073 |
| Adam Woodrow |
officer: President & Chief Commercial |
C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111 |
| Randall B. Brenner |
officer: Chief Development & Regulatory |
C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116 |
| Robert S Radie |
director |
101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355 |
| Rolf K Hoffmann |
director |
LORBEERWEG 7, WEGGIS V8 CH-6353 |
| Michael Bigham |
director, officer: Exec. Chairman of the Board |
890 WINTER STREET, WALTHAM MA 02451 |
| James D Dondero |
10 percent owner |
300 CRESCENT COURT, SUITE 700, DALLAS TX 75201 |
| Douglas W. Pagan |
officer: Chief Financial Officer |
75 KNEELAND STREET, BOSTON MA 02111 |
| Omega Fund Iv, L.p. |
10 percent owner |
888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRTK has been successfully added to your